

**Additional information pursuant to Art. 33, para 1, item 6
of the Ordinance 2 of 17.09.2003 on
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.
as of the 31st of December 2016**

1. Information on the changes in accounting policy during the reporting period, the reasons for them and how they affect the financial results and equity of the issuer.

The individual financial statements of Tchaikapharma High Quality Medicines Inc. have been prepared in accordance with International Financial Reporting Standards as adopted in the European Union.

More detailed information about Company's accounting policies can be found in section II.1. The basis of the preparation of the financial statements are the Appendices to the Interim Financial Report for the period 01.01.2016 – 31.12.2016.

2. Information on the results from organizational changes made within the issuer, such as restructuring, sale of companies from the economic group, in-kind contributions from companies, rental property, long-term investments, and suspension of operation:

The book value of investments in companies is as follows:

		31.12.2016	Share	31.12.2015	Share
		BGN '000	%	BGN '000	%
Tchaikapharma HQMAA Inc.	Bulgaria	1	1%	1	1%

3. The opinion of the Governing Body on the realization of the published forecasts for the current financial year, taking into account the results of the current quarter, and the information on the factors and circumstances that will affect the achievement of the forecast results at least for the next quarter – no update of the projected results.

4. For the public companies - data on persons holding directly and indirectly at least 5 percent of votes at the general meeting at the end of the quarter and changes in the votes held by persons since the end of the previous quarter:

SHAREHOLDERS	Shares	/%/	Shares	/%/
	31.12.2016.		30.09.2016	
Tihomir Kamenov	54 200 576	/95,76%/	54 217 496	/95,79%/

6. Information on pending legal, administrative or arbitration procedures relating to liabilities or receivables amounting to at least 10 percent of the company's equity – no such procedures.

Biser Georgiev
Executive Director